CORDIS
EU research results

CORDIS

English EN
Concerted action on seroconversion to AIDS and death in Europe

Concerted action on seroconversion to AIDS and death in Europe

Objective

CASCADE was established in 1997 as a collaboration between the investigators of 22 cohorts of persons with well-estimated dates of HIV seroconversion (seroconverters). It is currently a network of epidemiologists, statisticians, virologists and clinicians from lead HIV institutions in 13 European countries, Australia and Canada. Seroconverters are enrolled into the individual cohorts locally and nationally and are typically followed up life-long. CASCADE's main aim is to monitor newly infected individuals, as well as those already enrolled in studies, over the entire duration of HIV infection.

The main premise is that through pooling data we are able to address issues which cannot be reliably addressed from single studies alone. Our main objectives are to: estimate survival expectations and assess changes over time; assess the impact of adverse drug reactions on survival, particularly if therapy is started close to seroconversion, and monitor changes in the cause of death over time; examine any changes in the characteristics of the virus over time; determine the impact of transmitted resistance, virus subtype, and host genetic factors on response to therapy and clinical outcome; characterise the foci of recent HIV epidemics in Eastern Europe; characterise initial disease progression in new epidemic areas; examine the effect of co-infection on HIV disease and response to therapy; and develop new techniques to facilitate the co-ordination of HIV clinical research across European cohorts.

Follow-up data from seroconverters are unique in providing information from an individual's initial contact with HIV as events can, therefore, be related to roughly the same fixed time point in their disease. Seroconverters thus provide a unique opportunity to study HIV throughout its whole infection period and also enable us to examine the characteristics of recently acquired HIV infection in the population and changes over time.

Coordinator

MEDICAL RESEARCH COUNCIL

Address

20 Park Crescent
London

United Kingdom

Administrative Contact

Kholoud PORTER (Dr)

Participants (24)

Sort alphabetically

Expand all

UNIVERSIDADE NOVA DE LISBOA - INSTITUTO DE HIGIENE E MEDICINA TROPICAL

Portugal

UNIVERSIDAD MIGUEL HERNANDEZ

Spain

ROBERT KOCH-INSTITUTE

Germany

ULLEVAL UNIVERSITY HOSPITAL

Norway

NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS

Greece

HOSPICES CANTONAUX - CHUV (CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS)

Switzerland

HEALTH PROTECTION AGENCY

United Kingdom

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

United Kingdom

SYDDANSK UNIVERSITET

Denmark

MUNICIPAL HEALTH SERVICE

Netherlands

UNIVERSITY COLLEGE LONDON

United Kingdom

STATENS SERUM INSTITUTE

Denmark

TARTU ÜLIKOOL

Estonia

NATIONAL INSTITUTE OF HYGIENE

Poland

SAINT-PETERSBURG PASTEUR INSTITUTE

Russia

IMMUNOCLIN LIMITED

United Kingdom

"PERINATAL PREVENTION OF AIDS INITIATIVE" VOLUNTARY SOCIETY

Ukraine

INSTITUTO DE SALUD CARLOS III

Spain

ACADEMIC MEDICAL CENTER AT THE UNIVERSITY OF AMSTERDAM

Netherlands

INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE INSERM

France

ISTITUTO SUPERIORE DI SANITÀ

Italy

UNIVERSITÀ DEGLI STUDI DI MILANO

Italy

UNIVERSITÉ BORDEAUX 2

France

UNIVERSITÉ CLAUDE BERNARD LYON 1

France

Project information

Grant agreement ID: 18949

  • Start date

    1 March 2006

  • End date

    30 June 2010

Funded under:

FP6-LIFESCIHEALTH

  • Overall budget:

    € 1 700 000

  • EU contribution

    € 1 700 000

Coordinated by:

MEDICAL RESEARCH COUNCIL

United Kingdom